Erectile Dysfunction May Predict Heart Attacks An expert has written an article on bmj.com that suggests a link between heart attacks and erectile dysfunction. Dr Geoffrey Hackett (Good Hope Hospital, Birmingham, UK) says that erectile dysfunction gives a two to three year early warning of a heart attack, but doctors are largely ignoring the relationship.
Source: www.medicalnewstoday.comSt. Luke's Episcopal Hospital Earns Third Distinguished Hospital Award For Clinical Excellence™ From HealthGrades St. Luke's Episcopal Hospital announces it is the only hospital in the Texas Medical Center to receive the HealthGrades Distinguished Hospital Award for Clinical Excellence™ three years in a row. One of only 270 hospitals in the nation to receive this award, St.
Source: www.medicalnewstoday.comDeceiving Cell Walls Approximately 1.6 million people die worldwide every year as a result of pneumococcal infection, which causes grave illnesses, including pneumonia, meningitis, and middle-ear infections. Children and the elderly are especially at risk. Vaccines are only effective against a few of the pneumococcal types and increasing resistance to antibiotics is making treatment more difficult.
Source: www.medicalnewstoday.com'Rescue Course' Of Antenatal Steroids Improves Outcome In Premature Babies In a study presented at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, researchers unveiled findings that show that premature babies born before 34 weeks have a 31 percent reduction in serious complications when given a "rescue course" of Antenatal Corticosteroids (ACS) steroids with no adverse side effects noted.
Source: www.medicalnewstoday.comRexahn Completes Patient Enrollment In Phase IIa Clinical Trial Of ZoraxelTM To Treat Erectile Dysfunction Rexahn Pharmaceuticals, Inc. (NYSE Alternext US: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced the completion of enrollment in its Phase IIa clinical trial evaluating ZoraxelTM for treatment of Erectile Dysfunction (ED). The Company expects to have preliminary study results in March 2009.
Source: www.medicalnewstoday.comNoninvasive ExAblate(R) Treatment For Uterine Fibroids Is Cost-Effective, New Study Says GE Healthcare and InSightec announced that new data show that the non-invasive ExAblate® 2000 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system is more cost-effective than myomectomy or Uterine Artery Embollization (UAE). The study appears in the January 2009 issue (Vol. 25, Issue 1) of The International Journal of Technology Assessment in Health Care.
Source: www.medicalnewstoday.comBicycle Seat Design Can Directly Affect A Man's Sexual Function Long suspected by the 5 million recreational bike riders and sexual medicine experts, bicycle seat design-shorter noseless seats versus the standard protruding nose extended seat-can directly affect a man's sexual function, based on the nation's first prospective study of healthy policemen riding bikes on the job. The study is published in the current issue of the Journal of Sexual Medicine. Dr.
Source: www.medicalnewstoday.comYounger Women With Endometrial Cancer Can Safely Keep Ovaries, Avoid Early Menopause Journal of Clinical Oncology Summary of study being published online January 26, 2009 in the Journal of Clinical Oncology, showing no survival difference between premenopausal women with early-stage endometrial cancer whose ovaries were left intact during cancer surgery compared with those whose ovaries were surgically removed.
Source: www.medicalnewstoday.comClopidogrel bisulfate (marketed as Plavix) FDA to conduct safety review to evaluate differences in efffectiveness, genetic factors, potential drug interactions.
Source: www.fda.gov
# posted by Network @ 11:33 AM
